Robins, Adaptive Biotechnologies CSO, sells $148,500 in stock

Dr. Harlan Robins, the Chief Scientific Officer of Adaptive Biotechnologies Corporation, sold company stock valued at approximately $148,500 in a transaction executed in the United States on March 31, 2025. The sale was conducted as part of a pre-arranged trading plan, known as a 10b5-1 plan, which allows corporate insiders to schedule stock transactions in advance to avoid accusations of trading on non-public, material information. Such plans are a common and regulated practice for executives to manage their personal financial portfolios while maintaining compliance with securities laws. Adaptive Biotechnologies, headquartered in Seattle, Washington, is a commercial-stage biotechnology company pioneering the use of immune-driven data for the diagnosis and treatment of diseases. The company's core technology platform is designed to read the genetic code of the immune system's T-cell and B-cell receptors, with applications in developing clinical diagnostics and therapies for cancer, autoimmune disorders, and infectious diseases. As a key scientific leader, Dr. Robins's research and strategic direction are integral to the company's mission and technological advancements. While the sale represents a notable personal financial transaction, it is not necessarily indicative of the company's operational health or future prospects. Investors and market analysts routinely monitor insider transactions, including sales, for signals about executive confidence. However, sales under 10b5-1 plans are typically viewed as less informative than discretionary trades, as they are scheduled in advance. The transaction was formally filed with the U.S. Securities and Exchange Commission, ensuring transparency and adherence to regulatory requirements for public company insiders.